IE00B91XRN20 - Common Stock - After market: 54.96 0 (0%)
NASDAQ:PRTA (1/30/2023, 7:16:30 PM)-2.16 (-3.78%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/amc||Earnings (Next)||02-13 2023-02-13|
|Ins Owners||0.04%||Inst Owners||86.27%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The firm is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The firm's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.
PROTHENA CORP PLC
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60
CEO: Gene G. Kinney
Prothena (NASDAQ:PRTA) priced an underwritten public offering of 3.25M shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering...
Here you can normally see the latest stock twits on PRTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.